A Study to Assess the Effectiveness and Safety of AF-219 for Subjects with a Treatment Resistant Chronic Cough

Overview

Información sobre este estudio

The purpose of this study is to assess the effectiveness and safety of AF-219 given to subjects with a treatment resistant chronic cough.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Women and Men between 18 and 80 years of age inclusive
  • Have refractory chronic cough
  • Women of child-bearing potential must use 2 forms of acceptable birth control 
  • Have provided written informed consent
  • Are willing and able to comply with all aspects of the protocol

Exclusion Criteria

  • Current smoker
  • FEV1/FVC < 60%
  • History of upper or lower respiratory tract infection or recent significant change in pulmonary status within 4 weeks of the baseline visit
  • History of opioid use within 1 week of the baseline visit
  • Body mass index (BMI) <18 kg/m2 or ≥ 40 kg/m2
  • History of concurrent malignancy or recurrence of malignancy within 2 years prior to screening (not including subjects with <3 excised basal cell carcinomas)
  • Screening systolic blood pressure >160 mm Hg or a diastolic blood pressure >90 mm Hg
  • Clinically significant abnormal electrocardiogram (ECG) at screening
  • Significantly abnormal laboratory tests at screening
  • Pregnant or breastfeeding
  • Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the Investigator or sponsor, would make the subject inappropriate for entry into this trial

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Vivek Iyer, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20266929

Mayo Clinic Footer